Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DCTHNYSE:ENOVNASDAQ:EYENASDAQ:LMAT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCTHDelcath Systems$12.76-6.2%$14.71$7.17▼$18.23$473.64M0.87420,315 shs965,131 shsENOVEnovis$32.99+5.2%$33.05$28.83▼$49.83$1.79B1.7886,445 shs1.27 million shsEYENational Vision$24.20+5.2%$18.97$9.56▼$24.68$1.82B1.271.93 million shs3.65 million shsLMATLeMaitre Vascular$83.69+0.8%$83.58$71.42▼$109.58$1.88B0.82169,623 shs108,025 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCTHDelcath Systems+0.22%+2.56%-15.37%+8.19%+62.49%ENOVEnovis-1.32%+4.51%+0.13%-15.49%-30.62%EYENational Vision-0.69%+1.41%+16.15%+79.77%+75.78%LMATLeMaitre Vascular+0.58%-0.40%+1.07%-2.48%+0.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDCTHDelcath Systems3.3218 of 5 stars3.55.00.00.01.62.50.6ENOVEnovis3.428 of 5 stars3.43.00.00.02.71.71.9EYENational Vision2.5568 of 5 stars2.22.00.03.32.20.80.0LMATLeMaitre Vascular2.3241 of 5 stars2.21.03.30.01.62.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCTHDelcath Systems 3.00Buy$24.0088.09% UpsideENOVEnovis 2.80Moderate Buy$58.0075.81% UpsideEYENational Vision 2.44Hold$18.67-22.87% DownsideLMATLeMaitre Vascular 2.33Hold$97.8316.90% UpsideCurrent Analyst Ratings BreakdownLatest DCTH, LMAT, EYE, and ENOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025DCTHDelcath SystemsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.006/18/2025EYENational VisionBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.005/23/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $29.005/19/2025EYENational VisionBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetMarket Perform ➝ Market Perform$13.00 ➝ $19.005/14/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.005/12/2025EYENational VisionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$14.00 ➝ $17.005/9/2025ENOVEnovisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.005/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $57.005/9/2025EYENational VisionThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$13.00 ➝ $17.005/9/2025EYENational VisionCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$13.00 ➝ $21.005/8/2025EYENational VisionUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCTHDelcath Systems$37.21M11.94N/AN/A$2.15 per share5.93ENOVEnovis$2.11B0.89$20.24 per share1.63$45.10 per share0.73EYENational Vision$1.82B1.05$1.72 per share14.07$10.37 per share2.33LMATLeMaitre Vascular$219.86M8.60$2.41 per share34.77$15.00 per share5.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCTHDelcath Systems-$26.39M-$0.50N/AN/AN/A-26.38%-29.44%-20.75%8/4/2025 (Estimated)ENOVEnovis-$825.49M-$13.95N/A10.34N/A-37.65%5.99%3.44%8/6/2025 (Estimated)EYENational Vision-$28.50M-$0.33N/A89.633.37-1.40%3.44%1.40%8/6/2025 (Estimated)LMATLeMaitre Vascular$44.04M$1.9842.2738.572.1919.96%13.53%9.78%7/30/2025 (Estimated)Latest DCTH, LMAT, EYE, and ENOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025DCTHDelcath Systems$0.10$0.03-$0.07$0.03$16.83 million$19.80 million5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/7/2025Q1 2025EYENational Vision$0.32$0.34+$0.02$0.18$510.30 million$510.32 million5/1/2025Q1 2025LMATLeMaitre Vascular$0.50$0.48-$0.02$0.48$57.61 million$59.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCTHDelcath SystemsN/AN/AN/AN/AN/AENOVEnovisN/AN/AN/AN/AN/AEYENational VisionN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.96%N/A40.40%14 YearsLatest DCTH, LMAT, EYE, and ENOV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2025LMATLeMaitre Vascularquarterly$0.201%5/15/20255/15/20255/29/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCTHDelcath SystemsN/A15.9514.61ENOVEnovis0.522.551.32EYENational Vision0.290.540.35LMATLeMaitre Vascular0.4816.4913.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCTHDelcath Systems61.12%ENOVEnovis98.45%EYENational VisionN/ALMATLeMaitre Vascular84.64%Insider OwnershipCompanyInsider OwnershipDCTHDelcath Systems17.94%ENOVEnovis2.70%EYENational Vision2.70%LMATLeMaitre Vascular9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDCTHDelcath Systems6034.83 million28.58 millionOptionableENOVEnovis7,36757.12 million55.58 millionOptionableEYENational Vision13,41179.05 million76.92 millionOptionableLMATLeMaitre Vascular49022.59 million20.45 millionOptionableDCTH, LMAT, EYE, and ENOV HeadlinesRecent News About These CompaniesLeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Copeland Capital Management LLCJune 28 at 6:02 AM | marketbeat.comLeMaitre Vascular (NASDAQ:LMAT) Stock Price Down 3.5% - Should You Sell?June 26, 2025 | marketbeat.comLMAT LeMaitre Vascular, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.com11,286 Shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) Bought by Consolidated Planning CorpJune 23, 2025 | marketbeat.comJohnson Investment Counsel Inc. Buys 7,603 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)June 21, 2025 | marketbeat.comLeMaitre Vascular: Scaling Nicely As Global Demand BuildsJune 17, 2025 | seekingalpha.comLeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Conestoga Capital Advisors LLCJune 17, 2025 | marketbeat.com1 Small-Cap Stock with Exciting Potential and 2 to Keep Off Your RadarJune 16, 2025 | finance.yahoo.comRhumbline Advisers Sells 3,538 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)June 12, 2025 | marketbeat.com5,600 Shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) Acquired by Wesbanco Bank Inc.June 11, 2025 | marketbeat.comLeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Acquired by GAMMA Investing LLCJune 11, 2025 | marketbeat.com3 Low-Volatility Stocks in Hot WaterJune 10, 2025 | msn.comDividend Assets Capital LLC Makes New $3.88 Million Investment in LeMaitre Vascular, Inc. (NASDAQ:LMAT)June 10, 2025 | marketbeat.comLeMaitre Vascular, Inc. (NASDAQ:LMAT) is Bridge City Capital LLC's 10th Largest PositionJune 9, 2025 | marketbeat.comCompass Planning Associates Inc Has $988,000 Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)June 8, 2025 | marketbeat.comVest Financial LLC Invests $1.47 Million in LeMaitre Vascular, Inc. (NASDAQ:LMAT)June 8, 2025 | marketbeat.comCongress Asset Management Co. Decreases Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)June 7, 2025 | marketbeat.comLeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Acquired by Hennion & Walsh Asset Management Inc.June 6, 2025 | marketbeat.comJane Street Group LLC Sells 13,210 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)June 6, 2025 | marketbeat.comTwo Sigma Investments LP Has $2.43 Million Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)June 1, 2025 | marketbeat.comNuveen Asset Management LLC Decreases Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)June 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesRobinhood Director Sells Millions, But HOOD Stock Eyes GainsBy Gabriel Osorio-Mazilli | June 19, 2025View Robinhood Director Sells Millions, But HOOD Stock Eyes GainsCrowdStrike Eyes Breakout as Cyber Threats Boost DemandBy Chris Markoch | June 24, 2025View CrowdStrike Eyes Breakout as Cyber Threats Boost DemandSarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesBy Leo Miller | June 18, 2025View Sarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesSkyworks Stock Down 16% in 2025, Poised for AI Edge SurgeBy Chris Markoch | June 27, 2025View Skyworks Stock Down 16% in 2025, Poised for AI Edge SurgeToast Stock: A Fast-Growing Mid-Cap Eyeing Further UpsideBy Ryan Hasson | July 1, 2025View Toast Stock: A Fast-Growing Mid-Cap Eyeing Further UpsideDCTH, LMAT, EYE, and ENOV Company DescriptionsDelcath Systems NASDAQ:DCTH$12.76 -0.84 (-6.18%) Closing price 04:00 PM EasternExtended Trading$12.80 +0.04 (+0.31%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Enovis NYSE:ENOV$32.99 +1.63 (+5.20%) Closing price 03:59 PM EasternExtended Trading$33.02 +0.03 (+0.09%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.National Vision NASDAQ:EYE$24.20 +1.19 (+5.17%) Closing price 04:00 PM EasternExtended Trading$24.36 +0.16 (+0.66%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.LeMaitre Vascular NASDAQ:LMAT$83.69 +0.64 (+0.77%) Closing price 04:00 PM EasternExtended Trading$83.70 +0.00 (+0.01%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
